We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

MedImmune Acquires Spirogen and Invests in ADC Therapeutics

News   Oct 15, 2013

 
MedImmune Acquires Spirogen and Invests in ADC Therapeutics
 
 
 

RELATED ARTICLES

Fire, Sun or Electricity Powers Hand-held Cancer Detection Device

News

Device shows promise as a point-of-care detector of Kaposi sarcoma-associated herpesvirus in resource-limited settings.

READ MORE

Clinical Prospects for Stem Cells Begin to Emerge

News

There is now a critical mass of experts in this field and things are moving much faster, Stanford scientists say.

READ MORE

Ovarian Cancer Biomarker Can Predict Patient Therapy Response

News

Researchers have identified an independent prognostic factor - cancer/testis antigen 45 (CT45) - and have begun to elucidate it's actions. CT45 is associated with extended disease-free survival for women with advanced ovarian cancer.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE